Company intelligence / Profile preview

Suzhou Zanrong Pharmaceutical Technology

Suzhou, Jiangsu Sheng, China

Ownership: Private
Development stage: Other

Overview

Suzhou Zanrong Pharmaceutical Technology is developing multiple clinical-stage small-molecule oncology drugs, with two compounds in Phase 1 clinical trials (ZN-B-2262 for head and neck neoplasms targeting ATM and perzebertinib for HER2-positive breast cancer targeting HER2), and an additional discovery-stage program targeting BANF1 for neoplasms. As of June 2025, no clinical efficacy results have been published.[1][8]

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Suzhou Zanrong Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Zanrong Pharmaceutical Technology.

Explore the full profile